tailieunhanh - Báo cáo khoa học: "FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate | BioMed Central World Journal of Surgical Oncology Open Access Case report FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate Yiyan Liu Address Nuclear Medicine Service Department of Radiology University Hospital UMDNJ Newark New Jersey USA Email Yiyan Liu - liuyl@ Published 19 June 2008 Received II October 2007 World Journal of Surgical Oncology 2008 6 64 doi 1477-7819-6-64 Accepted 19 June 2008 This article is available from http content 6 I 64 2008 Liu licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background FDG PET-CT is generally not suitable for diagnosing prostate cancer because of low glycolysis of the tumor cells. Neuroendocrine differentiation of the prostate cancer is often associated with early visceral metastasis and dismal prognosis which is resulted from changed metabolic and regulatory pathways. Case presentation A case is reported in this paper that FDG PET-CT demonstrates intense uptake of neuroendocrine tumor of the prostate and multiple metastases. Conclusion There is high glycolysis and strong FDG-avidity of neuroendocrine tumor of the prostate which is similar to that of high grade of neuroendocrine tumor in other tissue and organs. In some selected cases of prostate neuroendocrine cancer whole body FDG PET-CT may be helpful for detection of metastatic disease. Background Positron emission tomography PET is a new imaging modality which has been widely used for detection of metastasis in various malignancies. The most used radiotracer F18-fluorodeoxyglucose FDG is for evaluation of glycolysis and glucose transporter expression. It is well known that most of malignant tumors display increased glucose metabolism. Unfortunately FDG-PET has not .